OIE Reference Laboratory Reports Activities in 2012
Name of disease (or topic) for Newcastle Disease which you are a designated OIE Reference Laboratory:
National Veterinary Services Laboratories Address of laboratory VS, APHIS, USDA P.O. Box 844, 1920 Dayton Avenue Ames, IA 50010 USA Tel.: (515) 337-7266
Fax: (515) 337-7397
e-mail address: [email protected]
website: http://www.aphis.usda.gov/animal_health/lab_info_services
Name (including Title) of Head of Dr. Elizabeth A. Lautner, Director Laboratory (Responsible Official): National Veterinary Services Laboratories
Name (including Title and Janice C. Pedersen, Position) of OIE Reference Expert: Microbiologist, Avian Viruses Section Diagnostic Virology Laboratory
Date of submission to the OIE 24 January 2013
Instructions
This form should be used by an OIE Reference Laboratory to report activities that took place from January through December of the past year (2012), unless otherwise stated, and must be submitted by the end of January every year.
Only those activities that concern the disease (or topic) for which the laboratory is recognised by the OIE should be mentioned. The questionnaire structure follows the Terms of Reference (ToRs) for OIE Reference Laboratories, available at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/introduction/
Each ToR (blue italicised text) has been placed as a heading covering the group of questions related to it.
Please note the red italicised text is given as guidance and should be deleted from your report and substitute with your data. Examples are based on past Annual Reports or have been invented.
The questionnaire represents a means of gathering information on activities carried out by OIE Reference Laboratories and making it available to OIE Member Countries and to the OIE Reference Laboratory network.
This annual report will remain available for consultation on the OIE web site: (http://www.oie.int/en/our-scientific-expertise/reference-laboratories/annual-reports/):
ToR: To use, promote and disseminate diagnostic methods validated according to OIE Standards
Annual reports of OIE Reference Centres, 2012 1 OIE RL for « Newcastle Disease » – « Ms. Janice C. Pedersen » – « United States of America »
Test recommended by the OIE Total number of test performed last year
Indirect diagnostic tests Nationally Internationally
Hemagglutination-inhibition (HI) for antibody 155 tests 0 tests detection/identification
Direct diagnostic tests Nationally Internationally
HI for virus serotype identification 1399 tests 107 tests
Real-time RT-PCR gene M 764 tests 9 tests
Real-time RT-PCR gene F (vNDV assay) 255 tests 6 tests
Real-time RT-PCR gene F (LoNDV assay) 216 tests 1 tests
Virus Isolation 4313 tests 8480 tests
Genomic Sequencing 124 tests 4 tests
Intracerebral pathogenicity index (ICPI) 82 tests 3 tests
ToR: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.
2. Did your laboratory produce or store imported standard reference reagents officially recognised by the OIE or other international bodies? Yes No
3. Did your laboratory supply standard reference reagents to OIE Member Countries? Yes No
4. Did your laboratory produce diagnostic reagents other than the OIE-approved standard reference reagents? Yes No
Amount Amount Name of recipient OIE Type of reagent Related supplied supplied Member Countries and available diagnostic test nationally internationally of institutions (ml, mg) (ml, mg) LaSota strain of APMV- VSN and rRT-PCR 0.6 ml 0.6 ml Ecuador 1 virus NDV virus (strain other 1.80 ml than LaSota) APMV-1 inactivated HI 228 ml 4.0 ml Ecuador antigen 20.0 ml Honduras 4.0 ml Latvia 36.0 ml Nicaragua 40.0 ml Panama 6.0 ml Saudi Arabia
2 Annual reports of OIE Reference Centres, 2012 OIE RL for « Newcastle Disease » – « Ms. Janice C. Pedersen » – « United States of America »
Amount Amount Name of recipient OIE Type of reagent Related supplied supplied Member Countries and available diagnostic test nationally internationally of institutions (ml, mg) (ml, mg) 20.0 ml Yemen Positive amplification rRT-PCR 2.25 ml 0.10 ml Colombia control Positive extraction rRT-PCR 296 ml control Negative extraction rRT-PCR 927 ml control APMV-1 positive HI and VSN 14.0 ml 20.0 ml Costa Rica control sera 2.0 ml Republic of Korea 4.0 ml Latvia 10.0 ml Nicaragua 2.0 ml Philippines 32.0 ml El Salvador Negative control sera HI and VSN 6.20 ml 5.0 ml Colombia 20.0 ml El Salvador ** Real-time RT-PCR rRT-PCR 2590 ml 180 ml Canada, Mexico proficiency test ** ISO 17043 accredited in 2012.
5. Did your laboratory produce vaccines?
Yes No
6. Did your laboratory supply vaccines to OIE Member Countries?
Yes No
ToR: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases
7. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?
Yes No
8. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?
Yes No
ToR: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries
9. Did your laboratory carry out diagnostic testing for other OIE Member Countries?
Yes No
Annual reports of OIE Reference Laboratories, 2012 3 OIE RL for « Newcastle Disease » – « Ms. Janice C. Pedersen » – « United States of America »
Name of OIE Date No. samples received for No. samples received for Member Country (dd/mm) provision of diagnostic support provision of confirmatory seeking assistance (i.e. from surveillance campaign) diagnoses Mexico 05/01 1
Belize 26/04 2
Belize 31/05 2
Dominican Republic 26/06 21
10. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?
Yes No
Name of the OIE Member Country How the advice was Purpose receiving a technical consultancy provided SENASICA, Mexico Review of the diagnostic tests and Written and verbal oversight procedures used for the surveillance and report provided to detection of NDV by CPA and other SENASICA, Mexico SENASICA regional laboratories. CPA, SENASICA, Mexico Preparation of Real-time RT-PCR proficiency Training event held at the panels and analysis of results NVSL SAG, Santiago, Chile Provided expert advice on inactivation of Monthly conference calls as paramyxoviruses, BSL-3 laboratory and part of the OIE twinning animal facility biosecurity procedures, project nucleotide sequencing methods and the production of reference reagents
ToR: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations
11. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?
Yes No
OIE Member Countries Partners Title of the study Duration Purpose of the study involved other than (Institutions) your country Evaluation of the 1 year Epidemiological study of Southeast Poultry Dominican Republic genotype classification ND viruses isolated in Research of ND viruses from the Central America and the Laboratory (SEPRL), Dominican Republic origin of those viruses Athens, GA
ToR: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases
12. Did your Laboratory collect epizootiological data relevant to international disease control?
Yes No
4 Annual reports of OIE Reference Centres, 2012 OIE RL for « Newcastle Disease » – « Ms. Janice C. Pedersen » – « United States of America »
13. Did your laboratory disseminate epizootiological data that had been processed and analysed?
Yes No
14. What method of dissemination of information is most often used by your laboratory?
(Indicate in the appropriate box the number by category)
a) Articles published in peer-reviewed journals:...... 5 b) International conferences:...... 1 c) National conferences:...... 4 d) Other:......
ToR: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards
15. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?
Yes No
a) Technical visits:...... 1 b) Seminars:...... c) Hands-on training courses:...... 3 d) Internships (>1 month):......
Type of technical training Country of origin of the expert(s) No. participants from the provided (a, b, c or d) provided with training corresponding country
c Mexico 3
a Mexico 4 laboratories
ToR: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned
16. Does your laboratory have a Quality Management System certified according to an International Standard?
Yes No
Quality management system adopted
ISO 17025
17. Is your laboratory accredited by an international accreditation body?
Yes No
Test for which your laboratory is accredited Accreditation body Hemagglutination-inhibition ILAC
Annual reports of OIE Reference Laboratories, 2012 5 OIE RL for « Newcastle Disease » – « Ms. Janice C. Pedersen » – « United States of America »
Real-time RT-PCR ILAC Virus Isolation ILAC
18. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned? (See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2012, Chapter 1.1.3 or Manual of Diagnostic Tests for Aquatic Animals 2012, Chapter 1.1.1)
Yes No
ToR: To organise and participate in scientific meetings on behalf of the OIE
19. Did your laboratory organise scientific meetings on behalf of the OIE?
Yes No
20. Did your laboratory participate in scientific meetings on behalf of the OIE?
Yes No
ToR: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results
21. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?
Yes No
22. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?
Yes No
Purpose of the proficiency tests: Role of your Reference Participating OIE (validation of a diagnostic protocol: Laboratory (organiser/ No. Ref. Labs/ specify the test; quality control of participant) participants organising OIE Ref. vaccines: specify the vaccine type, etc.) Lab. Performance of the USDA real-time PCR Organizer of proficiency 6 CFIA, Winnipeg, protocol for H5, H7 and M gene detection panel CAN (2 – analysis of proficiency test results participants) Interlaboratory comparison of VI, ICPI and Participant 4 CFIA, Winnipeg, nucleotide sequencing CAN
23. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?
Yes No
ToR: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results.
6 Annual reports of OIE Reference Centres, 2012 OIE RL for « Newcastle Disease » – « Ms. Janice C. Pedersen » – « United States of America »
24. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?
Yes No
No. participating Participating OIE Member Purpose for inter-laboratory test comparisons1 laboratories Countries Harmonising existing rRT-PCR test methods (MA and 14 Mexico Fusion gene assays) Interlaboratory comparison of VI, rRT-PCR, ICPI and 2 CPA and CENASA, Mexico nucleotide sequence tests Interlaboratory comparison of intracerebral 1 CPA, Mexico pathogenicity index (ICPI) assay
ToR: To place expert consultants at the disposal of the OIE
25. Did your laboratory place expert consultants at the disposal of the OIE?
Yes No
Listing of 2012 Publications for Newcastle Disease
Hines NL, Killian ML, Pedersen JC, Reising MM, Mosos NA, Mathieu-Benson C, Miller CL. (2012). An rRT-PCR assay to detect the matrix gene of a broad range of avian paramyxovirus serotype-1. Avian Dis. 56, 387-395.
Hines NL, Miller CL. (2012). Avian Paramyxovirus Serotype-1: A Review of Disease Distribution, Clinical Symptoms and Laboratory Diagnostics. Vet. Med. Int., 2012:708216.
Hines NL. Molecular analysis of avian paramyxovirus serotype-1. Iowa State University, 2012, 118 pages; ProQuest/UMI 12520.
Courtney SC, Susta L, Gomez D, Hines NL, Pedersen JC, Brown CC, Miller PJ, Afonso CL. (2012). Highly divergent virulent isolates of Newcastle disease virus from the Dominican Republic are members of a new genotype that may have evolved unnoticed for over two decades. J. Clin. Microbiol. 2012 Nov 28.
Courtney S, Gomez D, Susta L, Hines NL, Pedersen JC, Miller PJ, Afonso CL. (2012). Complete Genome Sequencing of a Novel Newcastle Disease Virus Isolate Circulating in Layer Chickens in the Dominican Republic. J. Virol. 86(17):9550.
Spackman E, Pedersen JC, McKinley ET, Gelb J. Optical specimen collection and transport methods for avian influenza and Newcastle disease from chickens. Submitted for publication to BMC Vet Research.
Pedersen, JC., NL Hines, ML Killian, AS. Predgen, BJ. Schmitt, Isolation of a Virulent Newcastle Disease Virus from Confiscated LaSota Vaccine. Submitted for publication to Avian Diseases.
Orsi MA, Camillo SCA, Domingues CS, Gouvêa MV, Peixoto JM, Zaroni MMH, Reischak D, Ribeiro SAM, Ramazotti A, Almeida FS, Brentano L, Pedersen JC, Spilki FR, CW Arns. Phylogenetic and/or Biological Diversities of Newcastle disease viruses isolated in Brazil during 2009-2010 passive surveillance. Submitted for publication.
1 See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3
Annual reports of OIE Reference Laboratories, 2012 7